• Cytotoxic Activity of Familact: A Probiotic Supplement
  • Zahra Sadat Yahyavi,1,* Mohammad Reza Fazeli,2 Mani Mirfeizi,3 Shima Aliebrahimi,4 Seyed Nasser Ostad,5
    1. Azad University Karaj
    2. University of Tehran
    3. Azad University Karaj
    4. University of Tehran
    5. University of Tehran


  • Introduction: Background: Lactobacillus and Bifidobacterium species are among the probiotics discussed due to their anti-cancer effects in the treatment of colorectal and breast cancers in recent studies. The aim of this study was to investigate the anticancer effect of Familact, a commercial probiotic capsule containing seven bacterial strains (L. casei, L. acidophilus, L. rhamnosus, L. bulgaricus, B. breve, B. longum and Streptococcus thermophilus).
  • Methods: Various cancer cell lines including Caco-2, HT-29, T47D and normal cell line L929 were treated with different concentrations of Familact. Using MTT assay, the cytotoxicity effect was investigated for each cell line and then flow cytometry analysis of apoptosis was evaluated.
  • Results: Cytotoxicity Effect of Familact The cytotoxic activity of Familact on L929, Caco-2, HT-29, and T47D cell lines was investigated using MTT assay. After treatment with serial concentrations of the drug for 48 h, the 50% inhibitory concentration (IC50) was assessed. Familact inhibited cell viability of HT-29, Caco- 2, T47D and L929 in a dose-dependent manner with an IC50 value of 37.4 ± 4.25, 75.41 ± 1.85, 75 ± 9.69 and 78.45 ± 6.8 μg/ml, respectively (Figure 1). Overall, Familact exhibited remarkable cytotoxicity to HT-29 while other aforementioned cell lines experienced moderate toxicity towards this drug. Flow Cytometric Analysis of Apoptosis The effect of Familact on induced apoptosis in L929, Caco-2, HT-29 and T47D cells was evaluated by Annexin V-FITC and PI staining. The flow cytometry analysis showed that in L929 normal cells, exposure to Familact increased the percentage of late apoptotic cells in comparison to untreated control cells while HT-29 cells experienced a two- fold increase in late apoptotic cell death (P<0.01). In the case of Caco-2 and T47D cells, Familact was less effective in this regard, implying different mechanisms of cell death may be involved (Figure2)
  • Conclusion: Promising results would be obtained using this probiotic complex as complementary therapy in the treatment of colon cancer. In addition, for the prevention and treatment of cancer, the discovery of new probiotic bacteria with anti-cancer properties seems necessary.
  • Keywords: Apoptosis, Breast Cancer, Colorectal Cancer, Familact, Prebiotic, Probiotics.